155 / 1498
0
10
20
30
40
50
60
70
80
90
100
Zevalin
Last
Rituximab
Last
Chemo-
therapy
Patients (%)
0
2
4
6
8
Zevalin
Last
Rituximab
Last
Chemo-
therapy
Months
Rituximab-Refractory Trial:
Patient Response to Zevalin
Overall response rate
Estimated duration of response
15%
CR
74%
6.4
32%
64%
4.4
6.5
n
=54
n
=54
n
=51
n
=17
n
=34
n
=17
P
=0.002
P
=0.002
Median TTP in responders 9.1 months (range: 3.5 to 25.9+ months)